Masimo

MASI

Capitalización de mercado USD 9424 M

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the “Merger Agreement”), by and among Masimo, Danaher Corporation (“Danaher”) (NYSE: DHR) and Mobius Merger Sub, Inc. (the “Merger Sub”) at Masimo's special meeting of stockholders held virtually on May 1, 2026 (.

MASI's SET pulse oximetry shows accurate, consistent readings in hospitalized newborns across all skin tones in the largest real-world study.

Investors looking for stocks in the Medical - Instruments sector might want to consider either DexCom (DXCM) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?

IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--A NICU study evaluating Masimo SET® pulse oximetry on hospitalized newborns found no clinically significant differences in accuracy across skin tones.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are ad.

Bridger Management sold 47,841 shares of Masimo in the fourth quarter. The move resulted in the quarter-end position value decreasing by $7.06 million.

Parkman Healthcare Partners initiated a 200,000-share stake in Masimo during the fourth quarter. The quarter-end position value rose by $26.01 million as a result.

Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.